ZEISS PALM MicroBeam IV module Rel 4.2

描述（由申请人提供）：本提案要求NCRR支持从蔡司（P.A.L.M. Microlaser Technologies, Carl Zeiss Group, Bernried, Germany）购买最先进的PALM MicroBEAM IV激光捕获显微解剖仪器（PALM MicroBEAM）。该设备将是俄亥俄州立大学（OSU）共享使用的第一台激光捕获设备。整个俄勒冈州立大学或附近的全国儿童医院都没有激光捕获显微解剖（LCM）核心设备。所要求的仪器将被安置在俄亥俄州立大学医学中心（OSUMC）的激光捕获分子核心设施（https://lcm.osu.edu/index.cfm）中。． 应教师的要求，已承诺为拟议的核心提供空间和相关资源。2008年5月，俄勒冈州立大学获得了著名的美国国立卫生研究院临床与转化科学奖（CTSA）。LCM新方法的开发是该奖项的优先领域。PI与另外两名研究人员一起获得了研究资助，以开发LCM样本的蛋白质组学和miR分析方法。这些方法现已准备好进行传播；俄勒冈州立大学CTSA宣布了匹配资金，用于传播通过激光捕获分子核心开发的方法给俄勒冈州立大学的研究人员。所要求的PALM MicroBeam具有专利的激光显微解剖和压力弹射（LMPC）技术。在DNA、RNA和蛋白质水平上对病理改变的细胞和组织进行分子检查已经彻底改变了病理学的研究和诊断。然而，各种活性细胞群混合的原代组织的固有异质性会影响分子研究的结果和解释。特别适合于研究空间分解生物学，LMPC使研究者能够分离小到单细胞甚至亚细胞片段的纯细胞群体样本，以进一步进行分子分析（基因表达，蛋白质组学）。该设备预计将直接提高至少14个（8个主要用户和6个次要用户）的生产力，目前资助的联邦研究补助金总计250万美元的年度直接成本。核心设施的长期目标是为OSUMC和附属研究机构的不同研究社区提供最新的LCM技术和应用。LCM仪器拨款申请的资金将改变俄勒冈州立大学联邦资助研究项目的能力，提高他们的生产力和竞争力，以争取未来的校外资金，这些资金可以影响NIH和/或俄勒冈州立大学其他额外的校外资金研究。

DESCRIPTION (provided by applicant): This proposal requests NCRR support for the acquisition of state-of-the-art PALM MicroBEAM IV laser capture micro-dissection instrument (PALM MicroBeam) from Zeiss (P.A.L.M. Microlaser Technologies, Carl Zeiss Group, Bernried, Germany). This equipment would be the first laser capture equipment for shared use in the Ohio State University (OSU). The entire OSU or nearby Nationwide Children's do not have a Laser Capture Micro-dissection (LCM) core facility. The requested instrument will be housed in Laser Capture Molecular Core facilities (https://lcm.osu.edu/index.cfm) in the Ohio State University Medical Center (OSUMC). ). Space and relevant resources have been committed for the proposed core in response to faculty requests. In May, 2008 OSU was awarded the prestigious NIH Clinical and Translational Science Award (CTSA). LCM novel methodology development was a priority area in this award. The PI together with two other investigators was awarded research grant to develop proteomics and miR profiling methods from LCM samples. These methods are now ready for dissemination; OSU CTSA has announced matching funds for dissemination of methodology developed via Laser Capture Molecular Core to OSU investigators. The requested PALM MicroBeam has the patented laser microdissection and pressure catapulting (LMPC) technology. The molecular examination of pathologically altered cells and tissues at the DNA, RNA, and protein level has revolutionized research and diagnostics in pathology. However, the inherent heterogeneity of primary tissues with an admixture of various reactive cell populations can affect the outcome and interpretation of molecular studies. Particularly suited to study spatially resolved biology, LMPC enables the investigator to isolate samples of pure cell populations as small as single cells or even sub cellular fragments for further molecular profiling (gene expression, proteomics). The equipment is expected to directly enhance the productivity of a minimum of 14 (8 major users and 6 minor users) currently funded federal research grants totaling > $ 2.5 million in annual direct costs. The long term goals of the core facility are to provide diverse research community of OSUMC and affiliated research institutions with the latest LCM technology and applications. The funding of this instrumentation grant application for LCM will transform the capability of the federally funded research programs at the OSU, increasing their productivity and competitiveness for future extramural funding that can impact NIH and/or other extra mural funded research at OSU. PUBLIC HEALTH RELEVANCE: PALM MicroBeam IV is high-throughput laser microdissection (LCM) equipment. Using this technology, individual cells and specific regions can be captured from clinically relevant small tissue section for genomic and proteomic analyses. The technology is best suited and is essential for human health relevant translational research.